The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
DIHYDROTESTOSTERONE AND THE PROSTATE: THE SCIENTIFIC RATIONALE FOR 5α-REDUCTASE INHIBITORS IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA
Abstract
PURPOSE: We reviewed the physiological and pathogenic role of dihydrotestosterone (DHT), evidence for the beneficial effects of decreasing DHT through 5alpha-reductase inhibition and the effects of altering the androgen balance with these agents. MATERIALS AND METHODS: A review of the relevant literature was done using published studies identified from the MEDLINE database. RESULTS: The androgens DHT and testosterone have complementary roles in male physiology. Each is mediated through the intracellular androgen receptor. It has been hypothesized that DHT may provide an amplification mechanism for testosterone, which could be a beneficial adaptation in men with low circulating testosterone. The recognition of the central role of DHT in benign prostatic hyperplasia (BPH) has changed the way the disease is viewed and has led to the introduction of 5alpha-reductase inhibitors, which can prevent and retard the progression of BPH by suppressing DHT synthesis. The 5alpha-reductase inhibitors decrease prostate volume. In doing so they improve symptoms and urinary flow, and decrease the risks of acute urinary retention and the need for BPH related surgery. The predominant drug related adverse events with 5alpha-reductase inhibitors are reproductive events, that is typically decreased libido, impotence and ejaculatory dysfunction. These events occur in a minority of men and tend to decrease with a longer treatment duration. CONCLUSIONS: DHT appears to have an obligatory role in the development of BPH. The role of 5alpha-reductase inhibitors in the treatment of BPH has been firmly established with an adverse events profile that is suitable for long-term use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Goodman and Gilman's the Pharmacological Basis of Therapeutics
Stigelman, W. H., & Pharm, D. (1986) · Military Medicine · doi:10.1093/milmed/151.1.386 · Cited by 6,782
The Influence of Finasteride on the Development of Prostate Cancer
Thompson, I. M., Goodman, P. J., Tangen, C. M., Lucia, M. S., Miller, G. J., Ford, L. G., Lieber, M. M., Cespedes, R. D., Atkins, J. N., Lippman, S. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030660 · Cited by 2,518
Sathianathen, N. (2021) · 50 Studies Every Urologist Should Know · doi:10.1093/med/9780190655341.003.0002 · Cited by 2,080
McConnell, J. D., Bruskewitz, R., Walsh, P., Andriole, G., Lieber, M., Holtgrewe, H. L., Albertsen, P., Roehrborn, C. G., Nickel, J. C., Wang, D. Z., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199802263380901 · Cited by 1,120
Self-citationRoehrborn, C. G., Boyle, P., Nickel, J. C., Hoefner, K., & Andriole, G. (2002) · Urology · doi:10.1016/s0090-4295(02)01905-2 · Cited by 729
Self-citationAmory, J. K., Watts, N. B., Easley, K. A., Sutton, P. R., Anawalt, B. D., Matsumoto, A. M., Bremner, W. J., & Tenover, J. L. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031110 · Cited by 475
Self-citationThe Localization of Androgen Receptors in Human Bone
Abu, E. O. (1997) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.10.3493 · Cited by 278
Andriole, G. L., & Kirby, R. (2003) · European Urology · doi:10.1016/s0302-2838(03)00198-2 · Cited by 175
Self-citationOverstreet, J. W., Fuh, V. L., Gould, J. E., Howards, S. S., Lieber, M. M., Hellstrom, W. J. G., Shapiro, S., Carroll, P. R., Corfman, R. S., Petrou, S. P., et al. (1999) · The Journal of Urology · doi:10.1016/s0022-5347(05)68270-5 · Cited by 148
Androgen-Induced Regrowth in the Castrated Rat Ventral Prostate: Role of 5 -Reductase
Wright, A. S., Douglas, R. C., Thomas, L. N., Lazier, C. B., & Rittmaster, R. S. (1999) · Endocrinology · doi:10.1210/endo.140.10.7039 · Cited by 145
Self-citation
Cited by
Bauman, D. R., Steckelbroeck, S., Williams, M. V., Peehl, D. M., & Penning, T. M. (2006) · Molecular Endocrinology · doi:10.1210/me.2005-0287 · Cited by 120
Rohrmann, S., Nelson, W. G., Rifai, N., Kanarek, N., Basaria, S., Tsilidis, K. K., Smit, E., Giovannucci, E., & Platz, E. A. (2007) · Urology · doi:10.1016/j.urology.2007.01.011 · Cited by 93
Androgen receptor abnormalities in castration-recurrent prostate cancer.
Nacusi, L. P., & Tindall, D. J. (2009) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.09.34 · Cited by 27
Self-citation
Metadata
- Authors
- ANDRIOLE, G., BRUCHOVSKY, N., CHUNG, L. W. K., MATSUMOTO, A. M., RITTMASTER, R., ROEHRBORN, C., RUSSELL, D., & TINDALL, D.
- Venue
- Journal of Urology
- Published
- 2004-10
- Volume
- 172
- Issue
- 4 Part 1
- Pages
- 1399-1403
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W2131899125
- Cited by
- 277
- References
- 20
- FWCI
- 11.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: DIHYDROTESTOSTERONE AND THE PROSTATE: THE SCIENTIFIC RATIONALE FOR 5α-REDUCTASE INHIBITORS IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA. https://app.cochat.ai/papers/10.1097/01.ju.0000139539.94828.29
- The paper
- ANDRIOLE, G., BRUCHOVSKY, N., CHUNG, L. W. K., MATSUMOTO, A. M., RITTMASTER, R., ROEHRBORN, C., RUSSELL, D., & TINDALL, D. (2004). DIHYDROTESTOSTERONE AND THE PROSTATE: THE SCIENTIFIC RATIONALE FOR 5α-REDUCTASE INHIBITORS IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA. Journal of Urology. https://doi.org/10.1097/01.ju.0000139539.94828.29
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.